KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Total Liabilities (2017 - 2025)

Twist Bioscience (TWST) has disclosed Total Liabilities for 9 consecutive years, with $182.0 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 19.23% to $182.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $182.0 million through Dec 2025, up 19.23% year-over-year, with the annual reading at $168.9 million for FY2025, 19.25% up from the prior year.
  • Total Liabilities for Q4 2025 was $182.0 million at Twist Bioscience, up from $168.9 million in the prior quarter.
  • The five-year high for Total Liabilities was $182.0 million in Q4 2025, with the low at $6.0 million in Q4 2021.
  • Average Total Liabilities over 5 years is $140.6 million, with a median of $152.7 million recorded in 2023.
  • The sharpest move saw Total Liabilities tumbled 90.26% in 2021, then soared 2627.42% in 2022.
  • Over 5 years, Total Liabilities stood at $6.0 million in 2021, then skyrocketed by 2627.42% to $163.6 million in 2022, then decreased by 12.75% to $142.8 million in 2023, then rose by 6.91% to $152.6 million in 2024, then grew by 19.23% to $182.0 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $182.0 million, $168.9 million, and $165.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.